Retatrutide is a novel peptide compound that acts as a triple agonist for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptors. This innovative peptide has shown significant potential in clinical research for obesity treatment and weight loss management.
Clinical studies have demonstrated that Retatrutide can produce weight loss exceeding 17.5% in overweight individuals with prediabetes. Its unique mechanism of action makes it particularly valuable for metabolic disorder research.
The peptide has the following amino acid sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSGAPPS3. This carefully designed structure allows for simultaneous activation of multiple metabolic pathways involved in glucose regulation and fat metabolism.
Our Retatrutide is supplied as a lyophilized powder with purity exceeding 99%, making it ideal for research applications. The product is available in multiple dosage options to accommodate various study requirements.
For research use only. Not for human consumption.